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Abstract: One may wonder why methylxanthines are so abundant in beverages used  
by humans for centuries, or in cola-drinks that have been heavily consumed since their 
appearance. It is likely that humans have stuck to any brew containing compounds with 
psychoactive properties, resulting in a better daily life, i.e., more efficient thinking, 
exploring, hunting, etc., however, without the serious side effects of drugs of abuse. The 
physiological effects of methylxanthines have been known for a long time and they are 
mainly mediated by the so-called adenosine receptors. Caffeine and theobromine are the 
most abundant methylxanthines in cacao and their physiological effects are notable. Their 
health-promoting benefits are so remarkable that chocolate is explored as a functional food. 
The consequences of adenosine receptor blockade by natural compounds present in 
cacao/chocolate are here reviewed. Palatability and health benefits of methylxanthines,  
in general, and theobromine, in particular, have further contributed to sustain one of the 
most innocuous and pleasant habits: chocolate consumption. 
Keywords: adenosine; adenosine receptors; adenosine receptor antagonist;  
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1. Introduction 
Xanthines are a variety of compounds produced by plants and animals that have not been studied as 
frequently as other substances of metabolism, such as ATP or GTP. Interestingly, these compounds 
belong to the family of purines and all human cells produce them. In fact, xanthine and its derivatives 
are intermediates in the production of GMP, GDP, and GTP in cells that depend on a salvage pathway 
that recycles intermediates of degradation back into GTP and nucleic acids. In addition, xanthine has a 
role in the catabolism of nucleotides and nucleic acids, as it is the precursor of uric acid, which is the 
final product of the catabolism of the purines (Figure 1A). The anabolic and catabolic metabolism in 
which xanthine is involved overlap, i.e., xanthine is at a crossroads from which GTP and nucleic acids 
may be synthesized by salvage mechanisms, or uric acid is produced to be eliminated in the urine. 
Interestingly, the benefits of xanthines in cacao are not at all related to the anabolic or catabolic purine 
metabolism in man. The active compounds in cacao that are structurally similar to xanthine are 
methylxanthines (Figure 1B), of which the action on human physiology is quite remarkable. Most 
consumers will be unaware that the psychoactive effects caused by cacao, coffee, or tea consumption 
results from blockade of adenosine receptors. 
Figure 1. (A) Xanthine as an intermediate of GTP and nucleic acid anabolism and catabolism. 
Rectangles in compounds highlight the xanthine unit; (B) Structures of methylxanthines, 
adenosine, and adenosine receptor antagonists structurally related to methylxanthines. 
Rectangles in compounds highlight the xanthine unit. 
 
2. Flavonols and Methylxanthines in Cacao 
Flavonols and methylxanthines are the most recognizable active components of cacao. Flavonols are 
polyphenolic structures that in cacao include catechin and derivatives, and B2, B3 and C1 procyanidins. 
Recent interest on these compounds derives from their antioxidant properties. Andújar et al. [1] have 
recently reviewed their potential benefits for human health. Among the myriad of health promoting 
effects suspected for antioxidants, anti-inflammatory actions seem to be promising. In fact, flavonols 
inhibit lipid peroxidation and affect production of lipid or lipid-derived molecules regulating the 
immune response and, recently, dietary cacao has been shown to ameliorate obesity-related 
inflammation in high fat-fed mice [2]. These molecules also seem to be key players in the increase of 
beneficial gut microbes (e.g., Lactobacilli) and the decrease of less beneficial ones (e.g., Clostridia) 
A B
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that follow cacao intake [3,4]. Hayek [5] has recently revisited data showing that cacao and/or 
chocolate modifies intestinal flora in the same way that prebiotics and probiotics do. As the functional 
interactions between gut microbiota and host metabolism are indeed shown in several studies (see for 
instance [6]), and result in health maintenance, some of the benefits of cacao may be due to this 
indirect mechanism. 
Potential health-promoting benefits of flavonols in cacao require more experimental effort. Hence, 
this review is centered on methylxanthines that (i) are enriched in cacao and cacao-based products;  
(ii) have central actions because they readily cross the blood brain barrier; and (iii) have been heavily 
studied from a physiological and a clinical point of view. 
3. Chocolate Appeal and Methylxanthine Reward 
Historical and anthropological data demonstrate that man has searched for nutrients and/or 
beverages that contained substances that helped, not only calorically, but also in terms of well-being. 
Apart from cacao, coffee, and tea, other methylxanthine-rich beverages have been used in different 
cultures. For instance tejate has been ceremonially important but also as an essential staple, especially 
during periods of hard fieldwork; the beverage is a source of energy, fat, and methylxanthines [7]. 
Organic residue analysis of ceramics from Cahokia, the largest prehispanic site north of Mexico, 
reveals the use of an Ilex-derived black drink that contained theobromine, caffeine, and ursolic  
acid [8]. Indeed, it is quite likely that methylxanthines are at the root of the big interest of humans for 
certain types of plants. 
Myths around the origins of coffee point to clear living benefits: (i) that of the lazy shepherd that 
begins to take good care of livestock after discovering and tasting coffee beans; and (ii) that of Omar, 
who, after being exiled to a desert discovered and enjoyed the decoctions obtained from roasted coffee 
beans. Implicitly these two stories take for granted the preservation of the habit of coffee consumption. 
Today, methylxanthines are still considered the main active components in cacao, coffee, and tea. 
Methylxanthines, acting on adenosine receptors in the central nervous system, enhance arousal, mood, 
and concentration levels [9], and make natural products containing methylxanthines to be explored as 
functional foods [10]. Drug reward in human evolution constitutes a paradox that has been recently 
detailed by Sullivan et al. [11]. Many of the drugs incorporated into human “diet”, from natural 
products, target neurons in the central nervous system and produce a variety of psychoactive, 
psychomotor, and neuroplastic effects whose description is out of the scope of the present review. 
However, apart from containing molecules acting on the central nervous system, successful beverages 
have appeal from a sensory perspective. In this aspect, methylxanthines appear as secondary, but 
important, players. Long time ago Schiffman et al. [12] reported that adaptation of the human tongue 
to methylxanthines potentiates taste. Concentrations of compounds used in the study were enough to 
block adenosine receptors, particularly the A1 subtype, while not affecting phosphodiesterase activity. 
The results were important to identify adenosine receptors as modulators of taste perception and to 
involve methylxanthines in the palatability of methylxanthine-containing foods. Although the 
molecular mechanism is unclear, the appeal of chocolate (and coffee and tea) to the sense of smell is 
generally known. A recent study has demonstrated that honeybees rewarded with caffeine, which 
occurs naturally in nectar of Coffea and Citrus species, were three times as likely to remember a 
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learned floral scent as were honeybees rewarded with sucrose alone [13]. This effect is mediated by 
adenosine receptors in the Kenyon cells in mushroom bodies of the insect brain that are similar in 
function to hippocampal neurons. Although adenosine receptors are present in human hippocampus, 
the cognition-enhancing effects of caffeine in healthy subjects seem to be limited [9]. However as 
indicated below, sustained coffee consumption seems to be protective against suffering from 
Alzheimer’s disease. 
4. Methylxanthine Levels 
On the one hand, methylxanthines are plant-produced natural products. On the other hand, many  
of the plants used to prepare beverages for human consumption are enriched in methylxanthines.  
Linked to three of the most consumed beverages (coffee, tea, and cacao) are the most popular 
methylxanthines: caffeine, theophylline, and theobromine (Table 1). Caffeine is the most abundant 
methylxanthine in coffee, its level being smaller in chocolate than in coffee. Unlike coffee, chocolate 
is enriched in theobromine, and the level of theophylline is quite low in both cacao and coffee. 
Therefore this review will focus on the two main methylxanthines in cacao: caffeine and theobromine. 
Trognitz et al. [14] have recently reported the contents of caffeine and theobromine in unfermented 
and fermented cacao from 100 cacao trees (individual genotypes) representing groups of nine genotype 
spectra grown in Nicaragua. Theobromine concentration in fermented samples was always higher than 
that of caffeine although the theobromine/caffeine ratio was highly variable: 1.9 to 10.6. This 
variability surely impacts on the relative content of the two compounds in the final product, i.e.,  
in chocolate. 
Table 1. Methylxanthine content in different cacao sources and products. 
Source Theobromine Caffeine Theophylline 
Raw ground paste (mg/kg) 33,000 5600 200 
Roasted ground paste (mg/kg) 36,000 330 Below limit of detection 
Cacao a (mg/kg) 26,000 2400 Not determined 
Cacao butter a (mg/kg) 140 400 Not determined 
Cacao a (mg/kg) 4621 489 Below limit of detection 
Baking chocolate a (mg/kg of sample) 10,040 1580 Below limit of detection 
Milka chocolate a (mg/kg of sample) 1004 56 Below limit of detection 
Dark chocolate b (mg/kg) 5000–7500 625–875 Not determined 
Modified from Lo Coco et al. [15], a Srdjenovic et al. [16]; and/or Risner [17]; b Bruinsma and Taren [18];  
The Hershey Company 2012; UK Joint Food Safety and Standards Group 1998.5. Safety of caffeine  
and theobromine. 
Consumers intuitively notice that the effects of coffee and chocolate are not equal and the reason 
for that remains obscure. Different pharmacokinetics of the two main methylxanthines in cacao may be 
a relevant factor. Caffeine plasma concentration levels in coffee drinkers is 2–10 mg/L [19] and, 
although there is considerable interindividual variability, plasma clearance in 19–21 year-old male 
volunteers is higher for caffeine (2.1 (mL/min) × kg) than for theobromine (1.2 (mL/min) × kg). 
Consequently, the half-life in plasma is higher for theobromine (7.2 h) than for caffeine (4.1 h) [20]. 
The potency of different methylxanthines on different targets should also be taken into account. 
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Whereas differences were not so marked in the case of adenosine receptors of the A1 subtype [21], the 
potency of blockade of methylxanthines in receptors of the A2 subtype (A2A plus A2B) was more 
diverse. IC50 values were 45 and 98 µM for, respectively, theophylline and caffeine, and 2500 µM for 
theobromine. To our knowledge theobromine has not been tested on A3 receptors although the partner 
compounds (caffeine and theophylline) display very poor affinity for them [17]. Actual affinities of 
caffeine and theophylline for the four human adenosine receptor subtypes expressed in heterologous 
cells are in the range: 4–39 µM with the affinity of theophylline higher by a factor of two to four [22]. 
A variety of alternative and/or complementary targets have been attributed to methylxanthines. 
High doses of methylxanthines achieved by supplements may have a variety of actions acting on a 
variety of targets. However, at the blood levels found after beverage consumption, these alternative 
effects, for instance the recently reported interaction with DNA to modify its structure [23], are 
probably not relevant. Also, this review focuses more on the effects due to cacao/chocolate intake, and  
less on any potentially beneficial or detrimental effect of methylxanthines in diet supplements or  
over-the-counter drugs. 
5. Safety of Caffeine and Theobromine 
Theobromine is toxic for a variety of mammals such as dogs [24]. In contrast, the toxicity of 
methylxanthines in humans is very low. Overwhelming scientific evidence on caffeine proves that 
moderate consumption of caffeine from natural sources is safe [25,26]; theobromine seems to be even 
safer for humans (see below). The main pharmacological effects of methylxanthines include central 
nervous system stimulation, diuresis, cardiovascular and metabolic effects, bronchial relaxation and 
increased secretion of gastric acids [27]. Despite central actions, these substances do not produce 
chemical dependence. Even caffeine, which was under suspicion for years, was excluded in 2004 from 
the list of substances banned by the World Anti-Doping Agency (WADA). Previously, in 1958,  
the Food and Drug Administration (FDA) of the United States included caffeine within the list of 
“generally recognized as safe” substances, and considered in 1987 that an oral intake equivalent to  
3–4 espresso cups (up to 300 mg/day) is safe for healthy adults. Caffeine is currently classified by the 
International Olympic Committee (IOC) as a substance restricted to 12 mg/L of urinary excretion, 
meaning that a dose of 300 mg (5 mg/kg for an athlete of 60 kg) would be within the limits accepted 
by the IOC. To our knowledge neither FDA, WADA, nor IOC has considered to put theobromine 
under close scrutiny. In both rodents and humans theobromine seems to be even safer than caffeine. 
Oral lethal dose 50 (DL50) for theobromine in rats is higher (1265 mg/kg) than for caffeine (192 mg/kg). 
One of the advantages of natural compounds that are safe and do not produce chemical dependence 
is that they may be delivered to humans in clinical trials or in controlled studies in healthy volunteers. 
In a recent study in which different doses of theobromine (250 mg–1 g) were compared with a single 
dose of caffeine (200 mg), Baggott et al. [28] reported that theobromine at normal intake ranges may 
contribute to the positive effects of chocolate, but at higher intakes, effects may become negative. 
Apart from confirming safety at the highest dose even used in humans, the authors found that 
theobromine lacked caffeine-like self-reported effects. The benefits of chocolate on mood seem to be 
mainly exerted by caffeine whereas theobromine may be involved in qualitatively different actions. 
Toxic effects may appear upon consumption of diet supplements enriched in caffeine [29] or if 
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caffeine is combined with drugs of abuse [30]. It should be also noted that the FDA announced in late 
2010 that caffeine is unsafe as additive to alcoholic beverages [31]. 
6. Mechanism of Action of Methylxanthines 
The first attempts to identify the potential targets for methylxanthines reported four different 
mechanisms. They were identified for caffeine acting on the central nervous system (reviewed [32]), 
but they may be extended to both other systems and other methylxanthines. They consist of: regulation 
of intracellular calcium level, phosphodiesterase inhibition, modulation of GABAA receptor action, and 
antagonism of adenosine receptors. Caffeine and probably other methylxanthines stimulate calcium 
release from intracellular stores but at a high µM threshold concentration and with a maximal effect at  
5–20 mM [33]. In addition, high concentrations are required for inhibition of phosphodiesterases [34], which 
are a family of enzymes that degrade cAMP and cGMP. It therefore seems that at the concentrations 
reached in dietary intake, these compounds are not effectively acting on phosphodiesterases or on 
calcium release. In addition, the low affinity of caffeine for GABAA receptors [35] suggested that 
normal human caffeine consumption is unlikely to produce doses high enough to produce anxiogenic 
effects by inhibiting these receptors. In summary methylxanthines are mainly acting as adenosine 
receptor blockers, although other mechanisms may also operate, especially under the intake of caffeine 
supplements or methylxanthine-enriched medications. 
7. Methylxanthines as Adenosine Receptor Antagonists 
Quite interestingly the majority of receptor antagonists are synthetic, i.e., developed in a  
laboratory, and a significant number of antagonist are used in therapy, for instance the so-called  
β-adrenergic-receptor blockers that are used in diseases of the cardiovascular system. Methylxanthines 
are natural products that behave as adenosine-receptor blockers and this is probably the reason cacao, 
coffee, and tea, have been so successful in the lifestyle of man. Four types of adenosine receptors have 
been identified that are widely distributed among human tissues. The widespread distribution of 
receptors fits with the presence of adenosine in every cell. In fact, adenosine exerts multiple actions in 
the central nervous, cardiovascular, etc., systems that depend on the activation of adenosine receptors. 
They belong to the superfamily of G-protein-coupled receptors and may bind to Gs or to Gi, i.e., 
activation of A1 and A3 subtypes leads to Gi-mediated decreases in cAMP and that of A2A and A2B 
leads to Gs-mediated increases in cAMP. The efficacy of blockers of A2A receptors, which may be 
structurally similar to methylxanthines (Figure 1B), are under clinical evaluation for Parkinson’s 
disease, and they have been also proposed to combat one of the prevalent arrhythmias, atrial 
fibrillation, for which no drug is yet available [36,37]. When adenosine receptor antagonists are 
compared, theobromine appears as less potent than caffeine (see above), yet some of the actions 
displayed by cacao seem qualitatively different to those of coffee. Evidence by Ciruela et al. [38] 
suggested that caffeine may have different potencies depending on the cellular ambient in which 
adenosine receptors are placed, and on the capability of forming dimeric structures (adenosine receptor 
heterodimers). More recently, Orru et al. [39] have demonstrated that different adenosine receptor 
antagonists may have different potencies in the same receptor in different cells or in different locations 
in the cell. In neurons the effect of a given antagonist may markedly differ on targeting pre- versus 
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post-synaptic adenosine receptors/receptor heterodimers. It is well known that the role of pre- is quite 
different from the role of post-synaptic receptors. This variable behavior of antagonists has, for 
instance, consequences in the effects of methylxanthines on motor control [39]. Therefore, a possibility 
that should be further explored is whether theobromine is preferentially acting on receptors, that on being 
blocked, lead to less unwanted effects than other methylxanthines such as caffeine or theophylline. This 
hypothesis would fully, or partly, explain why caffeine intake may lead to insomnia [40] whereas 
theobromine intake seems to favor sleep (see below). 
8. Physiological and Health Benefits of Methylxanthines in Cacao 
8.1. Theobromine in Oral Health 
Benefits of theobromine have reached oral health and an interesting study made with extracted 
human third molars proved a consistent and remarkable protection of the enamel surface upon 
application of a 200 mg/L theobromine solution [41]. It should be noted that these high levels are not 
attained in natural sources but the results indeed open the way to consider supplementing toothpaste 
and/or mouthwash liquids with theobromine. 
8.2. Methylxanthines in Respiratory Tract Diseases 
Usmani et al. [42] were the first to describe that theobromine is able to suppress cough in both 
guinea-pigs and humans without the side effects displayed by other antitussive drugs, such as codeine. 
In the latter, a randomized, double-blind, placebo-controlled study showed that theobromine 
suppresses capsaicin-induced cough with no adverse effects. The actions of theobromine appear to be 
peripherally mediated, as it was directly affecting capsaicin-induced sensory nerve depolarization of 
guinea-pig and human vagus nerve, suggestive of an inhibitory effect on afferent nerve activation.  
At the molecular level, the antitussive effect may be due to blockade of adenosine receptors, which 
were detected in the guinea-pig trachea in 1980 by Coleman, to inhibition of phosphodiesterases,  
or both [43]. These and other complementary findings have prompted a variety of clinical trials. One 
trial (registered at US National Institutes of Health—NIH—with Reference No. NCT01416480), for 
which no results have been yet posted, was completed to assess in acute cough the efficacy of a 
combined treatment of theobromine and levodropropizine, which is acting in the periphery on an  
ill-defined target. Another trial on “study of the safety and effectiveness of theobromine capsules to 
treat frequent long-term cough” (NIH, Reference No. NCT01656668) is, as of May 2013, recruiting 
participants. Cough is a troubling symptom for some patients with cancer. Accordingly, Halfdanarson 
and Jatoi suggested, in 2007, a trial on dark chocolate as antitussive in patients with cancer; to our 
knowledge, such a study has not been undertaken [44]. Whereas being clinically evaluated in different 
countries by Texas-based Pernix™ and London-based Seek™, theobromine is a first-in-class  
non-codeine non-opioid drug for cough that has successfully completed trials and regulatory review in 
South Korea (sold as AnyCough™). 
Epidemiological evidence suggests that theobromine and caffeine improve lung function and 
produce bronchodilatation in asthma patients [45,46]. Indeed, it has been demonstrated that patients 
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with asthma and bronchitis may self-administer coffee or cacao/chocolate to relieve symptoms, even 
though the benefit may come from positive reinforcement [47]. 
A further beneficial effect of methylxanthines on the airways is related with the apnea of 
prematurity (AOP). AOP is a common problem affecting premature infants, likely secondary to an 
immature respiratory system. Methylxanthine therapy is a mainstay of treatment of central apnea  
by stimulating the central nervous system and respiratory muscle function [48]. Caffeine, as a  
non-selective antagonist of adenosine receptors, may improve minute ventilation, CO2 sensitivity, 
diaphragmatic contraction, respiratory muscle function, and neural respiratory drive, while decreasing 
the hypoxic depression of breathing [49,50]. 
8.3. Methylxanthines as Psycho-Stimulants 
The psycho-stimulatory action of caffeine is well known [51] and, therefore, the caffeine in 
chocolate has a certain psycho-stimulant effect. The consensus related to a similar action of 
theobromine, which is the main methylxanthine component of cacao is in doubt. A careful study  
by Smit et al. [52] has demonstrated that the combination of caffeine and theobromine in the  
proportions found in cacao has psycho-stimulant effects. The authors performed two double-blind,  
placebo-controlled studies measuring the effects on cognitive performance and mood of the amounts 
of cacao powder and methylxanthines found in a 50 g bar of dark chocolate. In one of the studies 
voluntaries took visually identical portions of white chocolate, containing no methylxanthines, or low 
(8 mg caffeine + 100 mg theobromine) or high amounts (20 mg caffeine + 250 mg theobromine) of 
methyltxanthines. These three forms mimic, respectively, white, milk, and dark chocolate. Using a 
long duration simple reaction time task, a rapid visual information processing task, and a mood 
questionnaire, the results showed that the psycho-stimulant effect of chocolate is mainly due to the 
methylxanthines present [52]. 
8.4. Methylxanthines and Sleep 
Grander et al. [53] have studied dietary nutrients associated with short and long sleep duration in a 
US nationally representative sample (n = 5587) showing that the largest contributor to sleep duration 
was theobromine. These results contrast with those known for caffeine, which causes insomnia in a 
percentage of the general population. It is not well-defined why some individuals become tolerant and 
may have good sleep even after intake of heavy caffeine loads coming from coffee or cola drinks. 
Apart from tolerance mechanisms, Yang et al. [54] have reviewed the literature to conclude that 
predisposition to caffeine use is highly specific to caffeine itself, and that genome association studies 
link polymorphisms in adenosine and dopamine receptors to caffeine-induced anxiety and sleep 
disturbances. The fact that cacao consumption is not linked to sleep disturbances and that theobromine 
is beneficial must be taken into appreciation. 
8.5. Methylxanthines and Neurodegenerative Diseases 
Despite coffee consumption was considered unsuitable for humans suffering a wide range of 
illnesses, it is nowadays considered a healthy habit (with few exceptions). As an illustrative example 
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of the benefits of coffee consumption is a reduction in the incidence of two of the most prevalent 
neurodegenerative diseases: Parkinson’s [55] and Alzheimer’s [56,57]. The active component in 
actions on the central nervous system is assumed to be caffeine. Epidemiological studies, which are 
required to detect dietary styles that impact of the occurrence of a given disease, has to involve a high 
number of subjects and several years of duration. In the case of caffeine it seems that people that 
consume caffeinated coffee during the middle stages of life are less prone to suffer from neurological 
diseases when they get older. This hypothesis fits with the main role of methylxanthines, which is 
adenosine receptor blockade that in the brain results in higher neuronal activity thereby enabling a 
longer life for these cells. The higher neuronal activity may be due to a regulation in the perfusion of 
the brain [58–60] and/or an increase in cerebral oxygen consumption [61]. Another potential 
mechanism for neuroprotection may be an increased cerebrospinal fluid production [62,63]. 
8.6. Methylxanthines in Hypertension and Cardiovascular Diseases 
Methylxanthines have a variety of effects in heart and in blood vessels. As early as in 1910,  
Bond et al. [64] reported “no change in the velocity of circulation” through the coronary arteries and 
veins by the action of caffeine or theobromine. Even before, in the XIX Century, Askanazi [65] 
introduced the continued administration of theobromine to prevent the attacks in angina pectoris. In a 
personal account of the experience with theobromine, Dock [66] indicated that “in most of the cases  
of angina no relief was given, but in an important minority relief was immediate and complete”.  
The patients who improved were usually those with frequent, sometimes very severe, pain, moderate 
sclerosis of palpable vessels, and no other demonstrable circulatory disease. At that time, the physician 
also wrote that “no patient with angina pectoris or intermittent claudication should be considered 
intractable or subject to operation until theobromine has been tried”. The treatment was defined as 
inexpensive and harmless, but its efficacy has been surpassed by more recent therapeutic approaches. 
In the first half of the 20th Century, McGovern et al. [67] reported theobromine sodium salicylate 
as a vasodilator. Van den Bogaard et al. [68] have recently addressed the question of whether 
theobromine could be partially responsive of a blood pressure lowering effect. Consequently, a 
randomized, double-blind crossover trial with 41 subjects was undertaken to assess the effects of cacao 
with natural or high-dose theobromine on peripheral and central blood pressure. The two doses were 
carefully controlled, consisting of a natural dose of 106 mg of theobromine, or a theobromine-enriched 
cacao preparation with 979 mg of the compound. The results showed that a natural dose theobromine 
cacao did not significantly change either 24-h ambulatory or central systolic blood pressure compared 
with placebo. Furthermore, cacao drinks enriched with theobromine significantly increased 24-h 
ambulatory systolic blood pressure in a group of middle-aged subjects with high-normal blood 
pressure or grade I hypertension and low added risk of cardiovascular disease; despite the increased 
peripheral systolic blood pressure, central systolic blood pressure was lower two hours after 
consumption of theobromine-enriched cacao drinks. Whereas these data indicate that the cacao 
components (theobromine or else) at natural doses do not affect blood pressure in healthy and 
hypertension type I subjects, they may have a beneficial effect on other pathologies displaying 
hypertension [68]. In this sense, evidence from clinical studies has demonstrated that theobromine 
from cacao consumption significantly increases plasma HDL cholesterol levels, and decreases LDL 
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concentration in plasma, conferring cardiovascular protection and reducing the risk of coronary heart 
disease [69,70]. On the other hand, the difference between central and peripheral blood pressure  
upon consumption of the theobromine-enriched beverages, is an important result that merits  
further investigation. 
8.7. More Clinical Trials on Cacao Effects on Hypertension and Blood Vessel Status 
It is worth noting that diverse clinical trials for which no results are yet posted have been filed to 
evaluate the effectiveness of cacao and/or its components on hypertension. One of the trials is 
addressed to examine the acute and chronic effect of consumption of flavanol-rich chocolate on 
endothelium function and blood pressure in healthy pregnant women (registered at NIH with 
Reference No. NCT01659060). The aim of the “Consumption of Chocolate in Pregnant Women”, 
CHOCENTA study (registered at NIH with Reference No. NCT01431443) that is recruiting 
participants in 2013, is to investigate the acute and chronic effect of consumption of flavanol-rich 
chocolate on endothelium function in pregnant women at high risk for preeclampsia, which is a high 
blood pressure condition after 20 weeks of pregnancy, in a woman who previously had normal blood 
pressure. Finally, there is another, somewhat similar to the reported by van den Bogaard et al. [68], 
registered at NIH with Reference No. NCT01672840 that pursues to know the effects of cacao on 
ambulatory blood pressure and vascular function in patients with stage I hypertension. In this 
particular “Dose And Response to Cacao” (DARC) study, which as of May 2013 is recruiting 
participants, the effects of daily consumption of two doses of cacao-containing products (dark 
chocolate plus cacao beverage) for eight weeks will be assayed by measuring 24-h diastolic blood 
pressure, endothelial function, and arterial stiffness. 
8.8. Cacao in Insulin Resistance and Body Weight 
In the absence of adenosine fat cell lipolysis may be stimulated by potent phosphodiesterase 
inhibitors; the ability of xanthines to stimulate basal and noradrenaline-stimulated lipolysis is however 
in agreement with their potency as adenosine antagonists [71]. Grassi et al. [72] reported that  
short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity 
and a decrease in blood pressure in healthy persons. The effect was postulated to be due to flavonols in 
cacao although the involvement of adenosine receptor blockade cannot be ruled out [72–74]. It should 
be however noted that the benefits of the natural products in cacao may be offset by the heavy caloric 
intake due to chocolate consumption. The chocolate bars used in the Grassi et al. [72] study contained 
approximately 500 kcal, which roughly is 20%–25% of the recommended caloric intake per day. 
Unless sugar in cacao drinks or chocolate is totally or partially substituted by low caloric ingredients, 
the benefits of cacao on endocrine matters related to glucose and lipid handling can be contrasted, or 
even reversed, by increases in body weight [72,73]. 
9. Conclusions 
Nowadays, apart from the benefits for day-life activities, methylxanthines may be even considered 
instrumental for health-maintenance. The combination of theobromine and caffeine in cacao/chocolate 
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seems to be appropriate for having many of the expected benefits of methylxanthines with few 
drawbacks. In fact, chocolate/cacao does not generally produce insomnia or cause anxiety. The reason 
why the main methylxanthine in cacao, theobromine, has a differential effect when compared with 
caffeine or theophylline merits further investigation. Finally, it should be noted that the advantages of 
cacao/chocolate consumption may be counterbalanced by the high caloric intake associated to the 
sugar present in the preparations. Perhaps “diet” or “light” low-caloric preparations of cacao/chocolate 
should be explored to increase the health benefits of a pleasant experience. 
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